PGHL's numbers were decent propelled by VMS (~65% of sales), which grew ~18% YoY during the quarter as per IQVIA data.
- Sales were up 9.1% YoY to Rs. 298 crore
- EBITDA was at Rs. 90.8 crore, up 16.3% YoY with margins at 30.5%
- Consequent PAT was at Rs. 63.7 crore (up 15% YoY)
Key triggers for future price performance
- P&G's sustained efforts to strengthen power brands in VMS and other therapies via various patient engagement and commercial campaigns and doctors' involvement
- MNC pharma traits like strong brand stickiness, growth, earnings visibility, consistency (despite quarterly fluctuations) in performances, strong b/s
- Key differentiator for PGHL is that its core category is VMS. As a therapeutic category, this is likely to be rediscovered as daily supplements due to increased awareness in a post-Covid world
For details, click on the link below: Link to the report
Shares of Procter & Gamble Health Limited was last trading in BSE at Rs. 4191.15 as compared to the previous close of Rs. 4245.35. The total number of shares traded during the day was 358 in over 199 trades.
The stock hit an intraday high of Rs. 4249.20 and intraday low of 4160.00. The net turnover during the day was Rs. 1506269.00.